An experimental evaluation of the therapeutic window of the neuroprotective activity of a low-molecular nerve growth factor mimetic GK-2
Seredenin SB, Povarnina PY, Gudasheva TA · 2018 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 30132457
What does this source report?
GK-2 reduced infarct volume with experimental treatment starts between four and 24 hours after injury.
- Population and setting
- Rat transient middle cerebral artery occlusion; treatment-start timing experiment
- Evidence type
- Animal / experimental
- Preparation
- See the original report; formulation details require verification.
- Source language
- English
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- An animal treatment window cannot be used as a human treatment window.
- No human clinical outcome was measured.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Abstract reviewed
Source access and review scope
Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Seredenin SB, Povarnina PY, Gudasheva TA. An experimental evaluation of the therapeutic window of the neuroprotective activity of a low-molecular nerve growth factor mimetic GK-2 Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 30132457 2018.
Molekul research summary: https://molekul.io/research/stroke-30132457. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry